Sun Pharmaceutical Industries Ltd has entered into a definitive agreement to acquire Organon & Co, a US-based pharmaceutical company, for $11.75 billion. This strategic move marks one of the largest acquisitions in the pharmaceutical sector by an Indian company, aiming to strengthen Sun Pharma’s presence in the global market. Organon specializes in women’s health, biosimilars, and established brands, which complements Sun Pharma’s existing portfolio.
In a significant development for the pharmaceutical industry, this acquisition will enable Sun Pharma to diversify its product offerings and enhance its research and development capabilities. Organon’s strong foothold in the US market provides Sun Pharma with access to a broader customer base and advanced technologies. The deal is expected to close in the coming months, subject to regulatory approvals and customary closing conditions.
Meanwhile, this acquisition reflects the growing trend of Indian pharmaceutical companies expanding internationally to compete with global players. By integrating Organon’s assets, Sun Pharma aims to accelerate growth and innovation, potentially impacting drug availability and pricing worldwide. The transaction also highlights the increasing consolidation within the pharmaceutical industry as companies seek to leverage synergies and scale.
